GlassScriptPhysician profile
Juan Martinez
NPI 1962528828
$8,974.03
in general payments reported to CMS, 2019-2025
18 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $1,230 · 2021: $1,687 · 2022: $1,389 · 2023: $1,151 · 2024: $823 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987 · Education: $64.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.92 |
| Education | $64.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,628.67 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $1,949.32 | 2019-2025 | Biktarvy |
| Insmed, INC. | $1,112.79 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $1,037.82 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $977.88 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $477.56 | 2019-2025 | |
| Janssen Products, LP | $198.00 | 2020-2022 | |
| Theratechnologies INC. | $142.25 | 2019-2021 | |
| Emd Serono, INC. | $77.03 | 2025 | |
| Shionogi INC | $72.50 | 2020-2021 | |
| Astellas Pharma US INC | $64.32 | 2023 | Cresemba |
| Paratek Pharmaceuticals, INC. | $62.13 | 2021-2024 | Nuzyra |
| Napo Pharmaceuticals INC | $56.60 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Horizon Therapeutics Plc | $26.75 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $24.90 | 2021 | |
| Janssen Scientific Affairs, LLC | $20.23 | 2023 | Symtuza |
| Vyera Pharmaceuticals, LLC | $16.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.